MaxCyte Inc
LSE:MXCT
Intrinsic Value
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. [ Read More ]
The intrinsic value of one MXCT stock under the Base Case scenario is 228 GBX. Compared to the current market price of 299 GBX, MaxCyte Inc is Overvalued by 24%.
Valuation Backtest
MaxCyte Inc
Run backtest to discover the historical profit from buying and selling MXCT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MaxCyte Inc
Current Assets | 214.3m |
Cash & Short-Term Investments | 190.3m |
Receivables | 8.2m |
Other Current Assets | 15.8m |
Non-Current Assets | 52.4m |
Long-Term Investments | 18.4m |
PP&E | 33.3m |
Other Non-Current Assets | 700k |
Current Liabilities | 16.6m |
Accounts Payable | 400k |
Accrued Liabilities | 10.6m |
Other Current Liabilities | 5.6m |
Non-Current Liabilities | 16.8m |
Other Non-Current Liabilities | 16.8m |
Earnings Waterfall
MaxCyte Inc
Revenue
|
38m
USD
|
Cost of Revenue
|
-4.7m
USD
|
Gross Profit
|
33.3m
USD
|
Operating Expenses
|
-80.3m
USD
|
Operating Income
|
-47m
USD
|
Other Expenses
|
9.5m
USD
|
Net Income
|
-37.5m
USD
|
Free Cash Flow Analysis
MaxCyte Inc
MXCT Profitability Score
Profitability Due Diligence
MaxCyte Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
MaxCyte Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
MXCT Solvency Score
Solvency Due Diligence
MaxCyte Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
MaxCyte Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MXCT Price Targets Summary
MaxCyte Inc
According to Wall Street analysts, the average 1-year price target for MXCT is 765.99 GBX with a low forecast of 573.98 GBX and a high forecast of 937.69 GBX.
Shareholder Return
MXCT Price
MaxCyte Inc
Average Annual Return | 74.68% |
Standard Deviation of Annual Returns | 176.49% |
Max Drawdown | -83% |
Market Capitalization | 309.5m GBX |
Shares Outstanding | 104 130 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
Contact
IPO
Employees
Officers
The intrinsic value of one MXCT stock under the Base Case scenario is 228 GBX.
Compared to the current market price of 299 GBX, MaxCyte Inc is Overvalued by 24%.